THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY published Practical Tips for the Oncology Practice 6th Edition, a comprehensive business and management resource for oncology practices on June 8.
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
